Faster global financial news!
Drug Research and Development
-
Eli Lilly's new obesity drug delivers 23.3% weight loss in Type 2 diabetes patients
Eli Lilly's experimental drug eloralintide, when combined with Zepbound, achieved an average weight loss of 23.3% over approximately 11 months in patients with Type 2 diabetes. This compares to 14.8%
-
Novo Nordisk CEO signals M&A opportunities to strengthen drug pipeline amid competition
Novo Nordisk CEO Mike Doustdar told CNBC on Tuesday that the pharmaceutical giant is considering M&A opportunities to strengthen its drug pipeline, as it faces growing competition in the weight-loss m
-
Anthropic establishes Bay Area wet lab to push AI into drug development, aiming for Claude to direct lab robots for preclinical research
Anthropic establishes Bay Area wet lab to push AI into drug development, aiming for Claude to direct lab robots for preclinical research
-
Citi Survey: Only 24% of US Pharma Executives Optimistic About AI Success in Drug Discovery
Despite the near-universal adoption of artificial intelligence (AI) for drug research by pharmaceutical companies, few executives expect AI to genuinely lead to successful drug outcomes, according to
-
AI company Owkin signs drug discovery deal with Germany's Boehringer Ingelheim for cancer and immunology drugs
The agreement grants Boehringer Ingelheim access to Owkin's AI research platform and patient data to accelerate the development of treatments. This deal builds on a pilot project conducted by the comp
-
Moderna's market value of $63.7 billion is not supported by its shrinking commercial revenue of $2.2 billion, with the company's valuation resting on its drug pipeline.
Moderna's commercial business has contracted, with trailing-twelve-month revenue falling to $2.2 billion from $3.1 billion a year earlier, and an operating margin of -150.2%. The company's valuation i
-
Eli Lilly's new obesity drug delivers 23.3% weight loss in Type 2 diabetes patients
Eli Lilly's experimental drug eloralintide, when combined with Zepbound, achieved an average weight loss of 23.3% over approximately 11 months in patients with Type 2 diabetes. This compares to 14.8%
-
Novo Nordisk CEO signals M&A opportunities to strengthen drug pipeline amid competition
Novo Nordisk CEO Mike Doustdar told CNBC on Tuesday that the pharmaceutical giant is considering M&A opportunities to strengthen its drug pipeline, as it faces growing competition in the weight-loss m
-
Anthropic establishes Bay Area wet lab to push AI into drug development, aiming for Claude to direct lab robots for preclinical research
Anthropic establishes Bay Area wet lab to push AI into drug development, aiming for Claude to direct lab robots for preclinical research
-
Citi Survey: Only 24% of US Pharma Executives Optimistic About AI Success in Drug Discovery
Despite the near-universal adoption of artificial intelligence (AI) for drug research by pharmaceutical companies, few executives expect AI to genuinely lead to successful drug outcomes, according to
-
AI company Owkin signs drug discovery deal with Germany's Boehringer Ingelheim for cancer and immunology drugs
The agreement grants Boehringer Ingelheim access to Owkin's AI research platform and patient data to accelerate the development of treatments. This deal builds on a pilot project conducted by the comp
-
Moderna's market value of $63.7 billion is not supported by its shrinking commercial revenue of $2.2 billion, with the company's valuation resting on its drug pipeline.
Moderna's commercial business has contracted, with trailing-twelve-month revenue falling to $2.2 billion from $3.1 billion a year earlier, and an operating margin of -150.2%. The company's valuation i
- No data
Drug Research and Development
24H Trending
-
1
Oasis Network (ROSE) Token Analysis: Current Status and Future Outlook of a Privacy-Focused Public Chain
-
2
RBIES Coin: Rubies Cryptocurrency Status and Market Activity Analysis
-
3
How to Choose a Reliable Cryptocurrency Exchange Platform
-
4
VON Exchange and MOCA Perpetual Contracts: Market Dynamics Analysis
-
5
Global Bitcoin Legal Trading Platforms and an Analysis of OKX Platform
-
6
hiSQUIGGLE (HISQUIGGLE) Token Analysis: Value and Investment Considerations
-
7
Ethereum (ETH) Buying Guide: How to Choose a Reliable Platform
-
8
NEO Analysis: From "China's Ethereum" to Smart Economy Platform
-
9
CoinDesk Analysis: One Year After the Crypto Market's "10/10 Event," Bitcoin and Ethereum Liquidity Rebuilt, But Altcoins Still Face Risks
-
10
NGOT Analysis: Positioning, Total Supply, and Market Status
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
